0000000001103194

AUTHOR

Pedro Castro

showing 4 related works from this author

Safety and Outcome of Revascularization Treatment in Patients With Acute Ischemic Stroke and COVID-19: The Global COVID-19 Stroke Registry.

2023

Background and ObjectivesCOVID-19–related inflammation, endothelial dysfunction, and coagulopathy may increase the bleeding risk and lower the efficacy of revascularization treatments in patients with acute ischemic stroke (AIS). We aimed to evaluate the safety and outcomes of revascularization treatments in patients with AIS and COVID-19.MethodsThis was a retrospective multicenter cohort study of consecutive patients with AIS receiving intravenous thrombolysis (IVT) and/or endovascular treatment (EVT) between March 2020 and June 2021 tested for severe acute respiratory syndrome coronavirus 2 infection. With a doubly robust model combining propensity score weighting and multivariate regress…

Fibrinolytic Agents/therapeutic useCerebral Hemorrhage/complicationsStroke/epidemiologyBrain Ischemia/complicationsTreatment OutcomeIschemic Stroke/epidemiologyCOVID-19/complicationsHumansCohort studiesEndovascular Procedures/adverse effectsRegistriesNeurology (clinical)610 Medicine & healthIntracranial Hemorrhages/etiologyThrombolytic Therapy/adverse effectsResearch Article
researchProduct

Timing, Complications, and Safety of Tracheotomy in Critically Ill Patients With COVID-19

2021

Importance: The current coronavirus disease 2019 (COVID-19) pandemic has led to unprecedented needs for invasive ventilation, with 10% to 15% of intubated patients subsequently requiring tracheotomy. Objective: To assess the complications, safety, and timing of tracheotomy performed for critically ill patients with COVID-19. Design, Setting, and Participants: This prospective cohort study assessed consecutive patients admitted to the intensive care unit (ICU) who had COVID-19 that required tracheotomy. Patients were recruited from March 16 to April 10, 2020, at a tertiary referral center. Exposures: A surgical tracheotomy was performed for all patients following recommended criteria for use…

Mechanical ventilationbusiness.industrymedicine.medical_treatmentHazard ratio030208 emergency & critical care medicineIntensive care unitlaw.invention03 medical and health sciences0302 clinical medicineTracheotomyOtorhinolaryngologyInterquartile rangelawAnesthesiamedicineIntubationSurgery030212 general & internal medicineProspective cohort studybusinessOriginal InvestigationCohort studyJAMA Otolaryngology–Head & Neck Surgery
researchProduct

Prognostic Factors of Death in 151 Adults With Hemophagocytic Syndrome: Etiopathogenically Driven Analysis.

2018

Objective: To characterize the etiologies and clinical features at diagnosis of patients with hemophagocytic lymphohistiocytosis (HLH) and correlate these baseline features with survival using an etiopathogenically guided multivariable model. Patients and Methods: The Spanish Group of Autoimmune Diseases HLH Study Group, formed in 2013, is aimed at collecting adult patients with HLH diagnosed in internal medicine departments between January 3, 2013, and October 28, 2017. Results: The cohort consisted of 151 patients (91 men; mean age, 51.4 years). After a mean follow-up of 17 months (range, 1-142 months), 80 patients died. Time-to-event analyses for death identified a worse survival curve f…

medicine.medical_specialtymedicine.medical_treatmentHLH hemophagocytic lymphohistiocytosislaw.invention03 medical and health sciences0302 clinical medicinelawInternal medicineGC glucocorticoidEpidemiologymedicine030212 general & internal medicineSurvival analysislcsh:R5-920Hemophagocytic lymphohistiocytosisID immunosuppressive drugbusiness.industryMortality ratemedicine.diseaseICU intensive care unitIntensive care unitIVIG intravenous immunoglobulinImmunosuppressive drug030220 oncology & carcinogenesisCohortEtiologylcsh:Medicine (General)businessNK natural killerMayo Clinic proceedings. Innovations, qualityoutcomes
researchProduct

Global Impact of the COVID-19 Pandemic on Cerebral Venous Thrombosis and Mortality

2022

[Background and Purpose] Recent studies suggested an increased incidence of cerebral venous thrombosis (CVT) during the coronavirus disease 2019 (COVID-19) pandemic. We evaluated the volume of CVT hospitalization and in-hospital mortality during the 1st year of the COVID-19 pandemic compared to the preceding year.

StrokeVaccine-induced immune thrombotic thrombocytopeniaSDG 3 - Good Health and Well-beingCerebral venous thrombosisSARS-CoV-23112 NeurosciencesCOVID-19COVID-19; Cerebral venous thrombosis; Vaccine-induced immune thrombotic thrombocytopenia; Mortality; SARS-CoV-2; StrokeNeurology (clinical)MortalityCardiology and Cardiovascular Medicine3124 Neurology and psychiatryCOVID-19; Cerebral venous thrombosis; Mortality; SARS-CoV-2; Stroke; Vaccine-induced immune thrombotic thrombocytopeniaJournal of Stroke
researchProduct